Clinical trial
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
NCT00477672 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- July 31, 2009
- Enrollment
- 298 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.
parkinson's disease psychosis